

ACHIEVING A SUSTAINABLE HEALTH EQUITY

Biocon Biologics is uniquely positioned as a fully integrated 'pure play' biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. Building on the four pillars of Patients, People, Partners and Business, the Company is developing, manufacturing and commercializing, along with its partners, a range of high-quality, safe and effective biosimilars that offer affordable alternatives to expensive biologic medicines. Its cutting-edge R&D and global scale manufacturing have provided an innovative platform for 28 in-market and in-development biosimilars. Five of these are commercialized in several global markets with some of them being marketed in developed markets of US, Europe, Australia, Canada and Japan. The Company aspires to benefit 5 million patient lives with its biosimilars and attain a revenue milestone of USD 1 billion in FY22.

Biocon Biologics is a subsidiary of Biocon Ltd. (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013)

VISION

Most inspiring global leader in Biologics delivering affordable access to innovative and inclusive healthcare solutions, transforming patient lives.

MISSION

Fuelled by its 11 powerful Strategic Initiatives, Biocon Biologics aspires to touch 5MN patient lives and cross a revenue milestone of USD 1BN, by FY 22.



2
Development Partnerships
(Mylan, Sandoz)

FULLY INTEGRATED BIOSIMILARS PLAYER



840+
Registered Trademarks*



4500+
High-quality,
diverse talent pool



3
Manufacturing sites
(2 Bengaluru, 1 Malaysia)



28
Products in pipeline



1100+
Patents granted
(Biologics)*



25+
cGMP approvals from
International regulatory agencies**



5
Products taken from
Lab to Market



2
R&D sites
(Bengaluru, Chennai)



4
Office locations around the globe:
India, UK, US and Singapore

WORLD CLASS RESEARCH TALENT AND INFRASTRUCTURE

FACILITIES

85,000
sq. ft. state-of-the-art
research facility in
Bengaluru

8,000
sq. ft. microbial
and cell culture
pilot plants

60,000
sq. ft. research
center in Chennai

45,000
sq. ft. plant
in Malaysia



TALENT

4,500+
employees

20%
with MDs or PhD's

60%
with Master's degrees

Alumni
from leading Indian and
International universities

PATIENT CENTRIC INNOVATIVE HEALTHCARE SOLUTIONS

2+
billion doses of biosimilar
insulins provided for patients
globally so far

6
biosimilars commercialized
so far: Trastuzumab,
Pegfilgrastim, Bevacizumab,
Adalimumab#, rh-Insulin,
Insulin Glargine

2.1
million* patients served
globally through our
biosimilars in FY20

5
million patients targeted
to benefit through our
biosimilars by FY22

*Number of lives is calculated based on volume supplied

#Partner Mylan has in-licensed product, Biocon Biologics continues to have economic benefit

GLOBAL SCALE MANUFACTURING EXPERTISE

State-of-the-art manufacturing facilities -
mammalian & microbial

Facilities conform to most stringent cGMP guidelines

Regulatory approvals - EMA, US FDA, Health Canada,
ANVISA, COFEPRIS, PMDA, TGA, MCC etc.

New sterile injectables facility commercialized
in FY20

New state-of-the-art monoclonal antibodies facility
commissioned in FY20

SEVERAL FIRSTS TO OUR CREDIT IN THE AREA OF BIOSIMILARS



- 1st** company globally to get U.S. FDA approval for biosimilar Trastuzumab (2017)
- 1st** company from India to have a biosimilar approved in the U.S.: Trastuzumab (2017)
- 1st** company to get U.S. FDA approval for biosimilar Pegfilgrastim (2018)
- 1st** company from India to have a biosimilar commercialized in U.S.: Pegfilgrastim (2018)
- 1st** company to get approval for and launch biosimilar Trastuzumab in Australia, Canada (2019)
- 1st** to make biosimilar Insulin Glargine available on Australia's Pharmaceutical Benefits Scheme (PBS)



BIOCON BIOLOGICS HAS INCREASED ACCESS TO HIGH QUALITY INSULINS IN SEVERAL COUNTRIES

BIOCON BIOLOGICS IS AMONG THE TOP 5 INSULINS PLAYERS GLOBALLY, VERTICALLY INTEGRATED AND COST COMPETITIVE


01 Committed to universal access to rh-insulin by reducing prices for low and middle-income countries (LMIC) to less than **10 US cents/day**

02 rh-Insulin approved in **40+ countries**

03 Insulin Glargine approved in **60+ countries** 04 Independent development program for rh-insulin for the **US market**

05 In multiple countries like **Mexico** and **Malaysia**, nearly all insulin-requiring diabetics take **Biocon's Insulin**

MAJOR GLOBAL BIOSIMILARS PLAYER



Biocon Biologics India Limited

Biocon House, Semicon Park, Electronics City, Phase - II
 Hosur Road, Bengaluru, Karnataka 560100. India

Telephone: +91 80 6775 6775

Email: corporate.communications@biocon.com | Website: www.biocon.com

Follow us at

